Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results


Article info

Article history:
Accepted February 12, 2018

Associate Editor:
Giacomo Novara

Statistical Editor:
Andrew Vickers

Keywords:
Comparative effectiveness
Disease risk
Patient-reported function
Prostate cancer
Radiation
Surgery

Abstract

Background: Whether prostate cancer severity modifies patient-reported functional outcomes after radical prostatectomy (RP) or external beam radiotherapy (EBRT) for localized cancer is unknown.

Objective: The purpose of this study was to determine whether differences in predicted function over time between RP and EBRT varied by risk group.

Design, setting, and participants: The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population-based, observational study that enrolled men with localized prostate cancer in 2011–2012. Among 2117 CEASAR participants who underwent RP or EBRT, 817 had low-risk, 902 intermediate-risk, and 398 high-risk disease.

Outcome measurements and statistical analysis: Patient-reported, disease-specific function was measured using the 26-item Expanded Prostate Index Composite (at baseline and 6, 12, and 36 mo). Predicted function was estimated using regression models and compared by disease risk.

Results and limitations: Low-risk EBRT patients reported 3-yr sexual function scores 12 points higher than those of low-risk RP patients (RP, 39 points [95% confidence interval {CI}, 37–42] vs EBRT, 52 points [95% CI, 47–56]; p < 0.001). The difference in 3-yr scores for high-risk patients was not clinically significant (RP, 32 points [95% CI, 28–35] vs EBRT, 38 points [95% CI, 33–42]; p = 0.03). However, when using a commonly used
Prostate cancer severity is well known to influence oncologic outcomes after treatment for prostate cancer [1]. In the Prostate Cancer Intervention Versus Observation Trial, radical prostatectomy (RP) resulted in significant reductions in all-cause and disease-specific mortality among men with intermediate- and high-risk disease [2]. In the Scandinavian Prostate Cancer Group Study Number-4 trial, men who underwent RP for intermediate-risk disease had improved metastasis-free, cancer-specific, and overall survival than those who did not undergo treatment [3]. While these observations relate primarily to oncologic outcomes, they have nonetheless given rise to an emerging hypothesis that quality of life outcomes after surgery or radiotherapy may be dependent on the severity of the cancer at diagnosis.

Several biologically plausible reasons exist to suspect why the effects of treatment on patient-reported quality of life outcomes would vary by prostate cancer severity. First, the use of androgen-deprivation therapy along with external beam radiotherapy (EBRT) among patients with high-risk disease may lead to substantial decline in hormone and sexual functions, at least in the short term [4]. Second, surgery for high-risk patients is often more radical because surgeons typically avoid nerve-sparing techniques and sacrifice a larger portion of the membranous urethra at the apex [5,6]. As little data evaluating these hypotheses exist, a comparative study was needed to assess how sexual, urinary, bowel, and hormone functions varied by levels of prostate cancer severity after patients were treated for prostate cancer.

In this context, we tested the hypothesis that the effect of treatment on patient-reported urinary, bowel, hormone, and sexual functions would vary by prostate cancer severity according to the D’Amico risk classification system [1]. Since little is known about how the effects of treatment on patient-reported function vary by disease severity, these data will not only fill a substantial knowledge gap in the literature, but will also have important implications for patients and providers as they weigh individualized risks for treatment-related morbidity.
Tumor characteristics, treatment received, PSA levels, and treatment date were obtained by abstracting data from electronic health records. For patients without health record information, questionnaires and SEER registry data determined treatment received. Patients who underwent both RP and EBRT were categorized on the basis of primary treatment. Patients who received active surveillance, primary androgen-deprivation therapy, or cryoablation were excluded.

2.3. Statistical analysis

Patients’ baseline demographic, socioeconomic, and clinical characteristics were compared across cancer severity categories using Kruskal-Wallis and χ2 tests. To characterize typical changes in patient-reported function over time within each treatment group by the level of risk, we fit longitudinal regression models with EPIC scores as the response variable. The primary covariates were cancer severity, treatment type (RP or EBRT), and months since treatment; second-degree interactions among the three variables were included. To account for the within-subject correlation due to repeated observations, we used generalized estimating equations with an exchangeable working covariance matrix. The following covariates were included in the model: patient age at diagnosis, comorbidity tumor characteristics (PSA level corrected for 5α-reductase inhibitor use, Gleason score [≤6, 3+4, 4+3, or ≥8], and T stage [T1 or T2]), psychosocial measures (educational attainment, insurance type, employment type, marital status, and Short Form-36 physical function score, social support, CES-D score, participatory decision-making index [16], baseline function, and study site. The relationship between continuous variables and mean function was modeled using restricted cubic splines with three knots at the 10th, 50th, and 90th percentiles. We fit the models after multiple imputation using chained equations. Approximately 4%, 6%, 9%, and 15% of patients were missing the primary outcome at baseline and 6, 12, and 36 mo, respectively. The cancer severity–treatment interactions were assessed graphically for each functional domain by plotting the predicted EPIC domain scores from models derived from imputed datasets. Treatment effects were characterized by differences in function score at each time point between treatment groups, and differences in treatment effects among each risk group were characterized by the difference in these treatment effects between risk groups. Thus, our estimate of interest is a difference in differences (DID) accompanied by a 95% confidence interval (CI). All statistical analyses were performed using Stata 14.1 data analysis software (StataCorp. 2015. Release 14. College Station, TX: StataCorp LP) [19].

3. Results

Among the 2117 CEASAR participants in the analytic cohort, 817 (39%) had low-risk disease, 902 (43%) intermediate-risk disease, and the remaining 398 (19%) high-risk disease. Table 1 presents the distributions of selected demographic, socioeconomic, and clinical characteristics by disease-risk strata. In general, high-risk disease occurred more commonly among African-American men and men with lower levels of educational attainment, higher rates of non-Medicare/private insurance, lower levels of social support, lower levels of participatory decision making, and multiple medical comorbidities.

3.1. Sexual domain

Cancer severity modified the effect of treatment on sexual function scores as the differences in predicted function between RP and EBRT varied by risk group over time. Low-risk EBRT patients reported 3-yr sexual function scores that were 12 points higher than those of low-risk RP patients (RP, 39 points [95% CI, 37–42] vs EBRT, 52 points [95% CI, 47–56]; p < 0.001) and intermediate-risk EBRT patients reported scores that were 11 points higher than those of intermediate-risk RP patients (RP, 36 points [95% CI, 33–38] vs EBRT, 47 points [95% CI, 43, 51]; p < 0.001); however, high-risk EBRT patients reported scores that were only 6 points higher than those of high-risk RP patients (RP, 32 points [95% CI, 28–35] vs EBRT, 38 points [95% CI, 33–42]; p = 0.03; Table 2) [16]. Although all these comparisons are statistically significant, only the low- and intermediate-risk patients meet the predefined threshold of clinical significance for the EPIC sexual function domain (10–12 points).

To further investigate how the effect of treatment on sexual function relates conditionally to disease severity, we evaluated differences between low-, intermediate-, and high-risk patients within treatment groups (which are summarized for brevity in Fig. 1) [16]. Whereas high-risk RP patients reported sexual function scores that were 7.6 points lower than those of low-risk RP patients (95% CI, 3.5–12; p < 0.001), high-risk EBRT patients reported scores that were 14 points lower than those of low-risk EBRT patients at 3 yr (95% CI, 8.1–20; p < 0.001). This observation indicates that EBRT may lead to comparatively larger declines in sexual function when low- and high-risk patients are compared (DID, 6.4 points [95% CI, 0.02–13]; p = 0.049).

In a post hoc analysis of a commonly used definition for erectile function outcomes (ie, erections firm enough for intercourse), there was no significant effect modification of disease severity on outcomes after treatment. Approximately 35% of low-risk RP patients reported erections firm enough for intercourse at 3 yr compared with 33% of low-risk EBRT patients (p = 0.6); for intermediate-risk RP patients, approximately 29% reported erections firm enough for intercourse compared with 32% of EBRT patients (p = 0.4). Last, among high-risk patients, approximately 22% of RP patients reported erections firm enough for intercourse at 3 yr compared with 18% of EBRT patients (p = 0.4).

3.2. Incontinence domain

Unlike sexual function, cancer severity did not modify the effect of treatment on incontinence scores as the differences in predicted function between RP and EBRT between risk groups did not vary over time. At 3 yr, high-risk RP patients reported urinary incontinence scores that were 4 points lower than those of low-risk RP patients (95% CI, 0.8–8; p = 0.02; Table 3) [16]. Although the differences in scores are statistically significant, it is below the threshold of clinical significance for the EPIC incontinence domain (6–9 points) [10]. By contrast, differences between high- and low-risk EBRT patients were both statistically and clinically insignificant (0.6 [95% CI, –3.4 to 4.6]; p = 0.8). This resulted in a DID of 3.8 points over the study period (95% CI, −0.70 to 8.3; p = 0.1). The trajectories for urinary incontinence are shown in Figure 2 [16].

In a post hoc analysis of a commonly used definition for continence after treatment (ie, no leakage whatsoever),
there was no significant effect modification of disease severity on outcomes after treatment. Approximately 37% of low-risk RP patients reported no leakage whatsoever at 3 yr compared with 53% of low-risk EBRT patients \((p = 0.003)\); approximately 32% of intermediate-risk RP patients reported no leakage whatsoever at 3 yr compared with 53% of EBRT patients \((p < 0.001)\). Last, among high-risk patients, approximately 22% of RP patients reported no leakage whatsoever at 3 yr compared with 53% of EBRT patients \((p < 0.001)\).

### 3.3. Hormone, bowel, and urinary irritative domains

There were no clinically significant interactive effects between treatment and cancer severity for the bowel \((DID, 0.6 \text{ points} [95\% \text{ CI, } -1.9 \text{ to } 3.1]; p = 0.7)\), hormone (DID,


Table 2 – Adjusted predictions for EPIC sexual domain

<table>
<thead>
<tr>
<th>Risk group</th>
<th>Baseline Estimate (95% CI)</th>
<th>6 mo Estimate (95% CI)</th>
<th>12 mo Estimate (95% CI)</th>
<th>36 mo Estimate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radical prostatectomy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>61 (59–64)</td>
<td>30 (28–33)</td>
<td>35 (33–38)</td>
<td>39 (37–42)</td>
</tr>
<tr>
<td>High</td>
<td>59 (56–63)</td>
<td>23 (20–26)</td>
<td>27 (24–30)</td>
<td>32 (28–35)</td>
</tr>
<tr>
<td>Differences between low and high risk within RP group</td>
<td>4.0 (3.8–4.2)</td>
<td>1.4 (1.2–1.6)</td>
<td>1.0 (0.8–1.2)</td>
<td>1.0 (0.8–1.2)</td>
</tr>
</tbody>
</table>

| External beam RT |                            |                        |                         |                         |
| Low              | 63 (59–67)                 | 52 (47–56)             | 52 (48–56)              | 52 (47–56)              |
| Intermediate     | 62 (59–66)                 | 46 (42–50)             | 49 (45–52)              | 47 (43–51)              |
| High             | 55 (50–59)                 | 37 (33–42)             | 37 (33–42)              | 38 (33–42)              |
| Differences between low and high risk within EBRT group     | 4.7 (4.5–4.9)             | 1.3 (1.1–1.5)          | 1.0 (0.8–1.2)           | 1.0 (0.8–1.2)           |

CES-D = Center for Epidemiologic Studies Depression Scale; CI = confidence interval; EBRT = external beam radiotherapy; EPIC = Expanded Prostate Index Composite; RP = radical prostatectomy; RT = radiotherapy.

a Adjusted for patient age at diagnosis, comorbidity tumor characteristics (prostate-specific antigen corrected for 5-reductase inhibitor use, Gleason score ≤ 6, 3 + 4, 4 + 3, or ≥8, and T-stage [T1 or T2]), psychosocial measures (educational attainment, insurance type, employment type, marital status, Short Form-36 physical function score, social support, CES-D score, and participatory decision-making index [16]), and study site.

b Differences within the RP group were calculated by (RP_{low} − RP_{high}).

c p < 0.001.

d Differences between the EBRT group were calculated by (EBRT_{low} − EBRT_{high}).

Fig. 1 – Sexual function by risk and treatment modality. Sexual function trajectories were adjusted for patient age at diagnosis, comorbidity tumor characteristics (PSA corrected for 5α-reductase inhibitor use, Gleason score ≤6, 3 + 4, 4 + 3, or ≥8, and T-stage [T1 or T2]), psychosocial measures (educational attainment, insurance type, employment type, marital status, Short Form-36 physical function score, social support, CES-D score, and participatory decision-making index [16]), and study site. CES-D = Center for Epidemiologic Studies Depression Scale; EPIC = expanded prostate index composite; PSA = prostate specific antigen; RP = radical prostatectomy.

3.0 points [95% CI, 0.5–5.6]; p = 0.02, or irritative domain scores (DID, 2.7 points [95% CI, –0.1 to 5.5]; p = 0.06; Supplementary Fig. 1–3 and Supplementary Table 1).

4. Discussion

In this prospective, longitudinal, population-based study of functional outcomes after contemporary prostate cancer treatment, we observed that the patterns of sexual dysfunction after treatment for prostate cancer differed according to the severity of disease at diagnosis. For men with low- and intermediate-risk prostate cancer, EBRT was associated with better sexual function scores at 3 yr than RP; however, for men with high-risk prostate cancer, sexual function scores at 3 yr were similar between RP and EBRT. However, when using a commonly used binary definition of sexual function (erections firm enough for intercourse), no major differences were noted between RP and EBRT at 3 yr across low-, intermediate-, and high-risk disease strata. This supports the finding that high-risk men should not expect improved erections with EBRT compared with surgery. These data have important clinical implications for men who are considering treatment for high-risk prostate cancer.

Numerous studies have previously reported on the variation in functional outcomes by patient-level factors, such as age [20], race/ethnicity [21], comorbidity [22], and baseline function [23]. However, existing data regarding the variation of functional outcomes by cancer severity are notably lacking. In the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment study, the model predicted probability of having functional erections suitable for intercourse at 2 yr after surgery, and radiotherapy was shown to vary by levels of PSA [24]. However, PSA is only one factor that determines cancer severity, and substantial heterogeneity in cancer severity would be expected above and below the cutoff used in this study (10 ng/dl). Furthermore, the authors did not report how other important outcomes, such as bowel, urinary, and hormone functions, varied by levels of PSA. In a separate study of 62 patients who had RP and 54 patients who had EBRT, Takizawa et al. [25] found that high-risk patients undergoing EBRT reported better function in the sexual and urinary domains than high-risk patients undergoing RP. However, their study was relatively small, with limited power and questionable external validity.

The current study offers several important advantages over others in the literature. First, we used longitudinal methods and controlled for many known predictors of function after prostate cancer treatment. Longitudinal cohort studies offer numerous methodological benefits,
Table 3 – Adjusted predictions for EPIC incontinence domain

<table>
<thead>
<tr>
<th>Risk group</th>
<th>Baseline Estimate (95% CI)</th>
<th>6 mo Estimate (95% CI)</th>
<th>12 mo Estimate (95% CI)</th>
<th>36 mo Estimate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radical prostatectomy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>84 (83–86)</td>
<td>66 (64–68)</td>
<td>70 (68–72)</td>
<td>71 (69–73)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>86 (84–87)</td>
<td>63 (61–65)</td>
<td>69 (67–71)</td>
<td>69 (67–71)</td>
</tr>
<tr>
<td>High</td>
<td>85 (82–87)</td>
<td>61 (58–64)</td>
<td>67 (64–70)</td>
<td>67 (64–70)</td>
</tr>
<tr>
<td>Differences between low and high risk within RP group</td>
<td>5 (1–9)</td>
<td>3 (0.5 to 7)</td>
<td>4 (0.8–8)</td>
<td></td>
</tr>
<tr>
<td>External beam RT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>89 (86–91)</td>
<td>90 (87–92)</td>
<td>89 (86–91)</td>
<td>87 (84–90)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>94 (92–96)</td>
<td>91 (89–93)</td>
<td>92 (89–94)</td>
<td>89 (87–91)</td>
</tr>
<tr>
<td>High</td>
<td>93 (90–96)</td>
<td>88 (85–92)</td>
<td>89 (86–92)</td>
<td>87 (83–90)</td>
</tr>
<tr>
<td>Differences between low and high risk within EBRT group</td>
<td>2 (−3 to 5)</td>
<td>−0.7 (−5 to 3)</td>
<td>0.8 (−3 to 5)</td>
<td></td>
</tr>
</tbody>
</table>

CES-D = Center for Epidemiologic Studies Depression Scale; CI = confidence interval; EBRT = external beam radiotherapy; EPIC = Expanded Prostate Index Composite; RP = radical prostatectomy; RT = radiotherapy.

* Adjusted for patient age at diagnosis, comorbidity tumor characteristics (prostate-specific antigen corrected for 5-reductase inhibitor use, Gleason score [26], and T-stage [T1 or T2]), psychosocial measures (educational attainment, insurance type, employment type, marital status, Short Form-36 physical function score, social support, CES-D score, and participatory decision-making index [16]), and study site.

** Differences within RP group are calculated by (RP<sub>low</sub> - RP<sub>high</sub>).

*** p < 0.05.

**** Differences within the EBRT group are calculated by (EBRT<sub>low</sub> - EBRT<sub>high</sub>).

![Fig. 2 – Urinary incontinence by risk and treatment modality.](image)

including the ability to attribute outcomes to specific exposures; define the exposures according to presence, timing, and chronicity; and follow changes in the outcome over time. Second, baseline function was assessed and prespecified in the models. Poorer function at baseline can impact response and outcomes, which may produce misleading evidence regarding the effectiveness of treatments under study [26]. Assessing baseline function not only limited the impact of recall bias, but also allowed for the adjustment of pre-treatment differences between the surgery and radiotherapy cohorts. Third, we performed a comprehensive evaluation of disease-specific function after treatment for prostate cancer using clearly defined and broadly accepted survey instruments and categories of prostate cancer risk. The EPIC instrument is a psychometrically validated survey instrument designed to assess patient-reported outcomes after treatment for prostate cancer. Likewise, the D’Amico risk classification system is well known and commonly used among clinicians who treat prostate cancer. Fourth, our analysis was based on a large, population-based sample of ethnically diverse men diagnosed in the contemporary era and was appropriately powered for the question under study. Patients were accrued from five SEER registry catchment areas in addition to the CaPSURE database, which allowed for a population-based assessment of patient-reported outcomes. Unlike single institutional cohort studies or randomized trials, population-based studies offer insights into real-world outcomes among patients receiving treatment in the community.

Despite these strengths, several limitations should be acknowledged. First, clinically significant differences in EPIC domain scores are not firmly established, and as a result, we used published thresholds when interpreting these data [10]. For example, several comparisons in this study were statistically significant, but the point estimates for the differences did not always satisfy the criteria for clinical significance. Second, this is an observational study, and unmeasured confounding, such as differential clinician experience, access to high-quality care, differential frame of mind, hospital or provider-level characteristics, radiation techniques, or use of pelvic floor rehabilitation, may give rise to biased effect estimates. To address these concerns, the CESAR study contains a comprehensive set of patient-level variables, which, in combination with advanced inference model building, should minimize the effects of confounding. Third, radiation techniques are constantly evolving, and many intermediate-risk patients may not need androgen-deprivation therapy under modern dose-escalated radiation protocols. Fourth, many low-risk patients in this cohort received treatment, and this may not be reflective of future practice. Fifth, we acknowledge that the D’Amico classification system comprises relatively
crude categories, yet it remains widely used and understood, and has been extensively validated, while each of the alternative systems also has strengths and weaknesses. Finally, although we present the results of several statistical tests, we have not adjusted for multiple comparisons. However, our primary analysis was specified a priori, and we have been careful to interpret the results in the context of clinical relevance in addition to statistical significance [27].

We believe that these findings provide a valuable framework for a more comprehensive understanding of how the effects of treatment on patient-reported functional outcomes relate conditionally to the levels of D’Amico risk. In light of these data, we would advocate for the consideration of cancer severity when men are counseled regarding the pattern of harms after treatment for localized prostate cancer. With longer follow-up, these data could also lay the foundation for decision-support tools that target patients or providers, or both.

5. Conclusions

For men with low- and intermediate-risk prostate cancer, EBRT was associated with higher sexual function scores at 3 yr than RP; however, for men with high-risk prostate cancer, sexual function scores were similar between RP and EBRT. This observation holds even when using a binary definition of sexual function. Men with high-risk prostate cancer should be counseled that EBRT and RP are associated with similar sexual function outcomes at 3 yr.

Author contributions: Mark Douglas Tyson II had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Penson, Barocas, Greenfield, Goodman, Hamilton, Cooperberg.

Acquisition of data: Conwill, McCollum, Paddock, Stroup, Hashibe, Wu.

Analysis and interpretation of data: Koyama, Tyson.

Drafting of the manuscript: Tyson.

Critical revision of the manuscript for important intellectual content: Lee, Resnick, Hoffman, Penson.

Statistical analysis: Koyama, Tyson.

Obtaining funding: Penson.

Administrative, technical, or material support: Conwill, McCollum.

Supervision: Penson, Barocas.

Other: None.

Financial disclosures: Mark Douglas Tyson II certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Funding and role of the sponsor: This work was supported by the National Cancer Institute at the National Institutes of Health (5T32CA106183 to M.D.T.), by the American Cancer Society (MSRG-15-103-01-CPHPS to M.J.R.), by the US Agency for Healthcare Research and Quality (1R01HS019356, 1R01HS022640-01), and through a contract from the Patient-Centered Outcomes Research Institute.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.eururo.2018.02.012.

References


